Q-omics provides the consensus-scored CORO2B profile across patient tissues and cancer cell-line models. CORO2B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CORO2B is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, CORO2B protein abundance shows 27,175 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where CORO2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CORO2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CORO2B survival associations across molecular data types. CORO2B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CORO2B RNA expression–survival associations across cancer types. High CORO2B expression shows unfavorable associations in UVM, HNSC, KIRC, LGG and LUSC, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CORO2B RNA expression.
This table summarizes CORO2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CORO2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CORO2B shows lower tumor expression in KIRC, THCA, COAD, LUAD, KICH and LUSC. The KIRC box plot shows higher CORO2B RNA expression in normal versus tumor tissue (log2 FC = −2.517, t-test p < 0.001).
This table shows molecular features associated with CORO2B in patient tissues and cancer cell lines. In patient samples, CORO2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CORO2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
